Nature Reviews Neurology

Article	Citations
Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?	1637
Technology of deep brain stimulation: current status and future directions	477
Recovery from disorders of consciousness: mechanisms, prognosis and emerging therapies	365
Blood GFAP as an emerging biomarker in brain and spinal cord disorders	335
Maternal immune activation and neuroinflammation in human neurodevelopmental disorders	309
Diagnosis and management of migraine in ten steps	275
Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease	225
Prodromal Parkinson disease subtypes — key to understanding heterogeneity	213
Peripheral and central immune system crosstalk in Alzheimer disease — a research prospectus	205
Developing the ATX(N) classification for use across the Alzheimer disease continuum	183
Post-traumatic stress disorder: clinical and translational neuroscience from cells to circuits	182
Cycles in epilepsy	173
Synaptic degeneration in Alzheimer disease	172
Improving clinical trial outcomes in amyotrophic lateral sclerosis	170
The microbiome–gut–brain axis in Parkinson disease — from basic research to the clinic	161
Advances in local therapy for glioblastoma — taking the fight to the tumour	159
Functional roles of reactive astrocytes in neuroinflammation and neurodegeneration	155
Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours	149
Neurological infection with SARS-CoV-2 — the story so far	148
Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility	146
B cells in multiple sclerosis — from targeted depletion to immune reconstitution therapies	143
The effects of the COVID-19 pandemic on people with dementia	141
The human connectome in Alzheimer disease — relationship to biomarkers and genetics	135
Stroke in Africa: profile, progress, prospects and priorities	131
Circadian rhythms in neurodegenerative disorders	124

Global epidemiology of migraine and its implications for public health and health policy	123
The inter-relationship between delirium and dementia: the importance of delirium prevention	115
Human cerebral organoids — a new tool for clinical neurology research	112
The metabolic basis of epilepsy	108
Apparent changes in the epidemiology and severity of multiple sclerosis	107
Single-cell and spatial transcriptomics: deciphering brain complexity in health and disease	98
Psychosis in Alzheimer disease — mechanisms, genetics and therapeutic opportunities	97
Mechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis	97
The neuroanatomical–functional paradox in spinal cord injury	96
Non-neuronal cells in amyotrophic lateral sclerosis — from pathogenesis to biomarkers	96
Hypomyelinating leukodystrophies — unravelling myelin biology	95
Pharmacological brain cytoprotection in acute ischaemic stroke — renewed hope in the reperfusion era	92
The importance of ongoing international surveillance for Creutzfeldt–Jakob disease	91
The case for low-level BACE1 inhibition for the prevention of Alzheimer disease	89
Gene–environment interactions in Alzheimer disease: the emerging role of epigenetics	86
Sex and gender in neurodevelopmental conditions	82
Hope for patients with neuromyelitis optica spectrum disorders — from mechanisms to trials	81
White matter injury in infants with intraventricular haemorrhage: mechanisms and therapies	78
Amyloid-β: a potential link between epilepsy and cognitive decline	78
Neurobehavioural comorbidities of epilepsy: towards a network-based precision taxonomy	76
Changing demography and the challenge of dementia in India	75
The role of glial cells in multiple sclerosis disease progression	74
Alzheimer disease in African American individuals: increased incidence or not enough data?	72
Epstein–Barr virus as a leading cause of multiple sclerosis: mechanisms and implications	72
Astrocytes in the initiation and progression of epilepsy	71
Can we learn lessons from the FDA’s approval of aducanumab?	71
Aducanumab and the FDA — where are we now?	71
Bruton tyrosine kinase inhibitors for multiple sclerosis	71
The role of the gut microbiota in multiple sclerosis	70
Identification of clinically relevant biomarkers of epileptogenesis — a strategic roadmap	69
Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies	69
Tau-targeting therapies for Alzheimer disease: current status and future directions	64
A global view of the genetic basis of Alzheimer disease	63
Multimodal brain and retinal imaging of dopaminergic degeneration in Parkinson disease	63
Cluster headache pathophysiology — insights from current and emerging treatments	62
Early-stage Alzheimer disease: getting trial-ready	62
The multiple sclerosis prodrome	61
Mind the gap: from neurons to networks to outcomes in multiple sclerosis	54
Nuclear pore complexes — a doorway to neural injury in neurodegeneration	53
Hormonal influences in migraine — interactions of oestrogen, oxytocin and CGRP	53
Social determinants of health in multiple sclerosis	52
Autonomic manifestations of epilepsy: emerging pathways to sudden death?	52
The neurovascular unit and systemic biology in stroke — implications for translation and treatment	52
Rapidly progressive dementias — aetiologies, diagnosis and management	50
MRI biomarkers in neuro-oncology	49
The approval of Aduhelm risks eroding public trust in Alzheimer research and the FDA	48
Cognitive adverse effects of chemotherapy and immunotherapy: are interventions within reach?	46
Genetics of common cerebral small vessel disease	46
Neurofilaments as biomarkers in neurological disorders — towards clinical application	45
Review and update of the concept of embolic stroke of undetermined source	45

Cognitive impairment in people living with HIV: consensus recommendations for a new approach	45
Perinatal stroke: mapping and modulating developmental plasticity	43
Guillain–Barré syndrome in low-income and middle-income countries: challenges and prospects	42
Lesions without symptoms: understanding resilience to Alzheimer disease neuropathological changes	41
Closing the loop for patients with Parkinson disease: where are we?	41
Why won’t it stop? The dynamics of benzodiazepine resistance in status epilepticus	39
Global synergistic actions to improve brain health for human development	39
Inflammation in multiple sclerosis: consequences for remyelination and disease progression	38
Multifaceted microglia — key players in primary brain tumour heterogeneity	38
Refining oxytocin therapy for autism: context is key	37
Positron emission tomography in multiple sclerosis — straight to the target	37
From the prodromal stage of multiple sclerosis to disease prevention	37
The role of astrocytic α7 nicotinic acetylcholine receptors in Alzheimer disease	36
Functional brain networks in the evaluation of patients with neurodegenerative disorders	35
hiPSCs for predictive modelling of neurodegenerative diseases: dreaming the possible	35
Molecular biomarkers for vascular cognitive impairment and dementia	34
Emerging therapies to target CNS pathophysiology in multiple sclerosis	34
Applying genomic and transcriptomic advances to mitochondrial medicine	33
Lecanemab trial in AD brings hope but requires greater clarity	33
Prospective memory impairment in neurological disorders: implications and management	33
Dissecting the complexities of Alzheimer disease with in vitro models of the human brain	32
Vaccination and immunotherapies in neuroimmunological diseases	30
Maximizing treatment efficacy through patient stratification in neuropathic pain trials	30
Why functional neurological disorder is not feigning or malingering	29
Epigenetic genes and epilepsy — emerging mechanisms and clinical applications	28
Genetic testing in dementia — utility and clinical strategies	27
Schizophrenia: from neurochemistry to circuits, symptoms and treatments	27
The noradrenergic subtype of Parkinson disease: from animal models to clinical practice	27
Adaptive and maladaptive myelination in health and disease	26
Neurogenetic disorders across the lifespan: from aberrant development to degeneration	26
Neuroprognostication: a conceptual framework	26
Biomarker-based staging of Alzheimer disease: rationale and clinical applications	26
Neuropsychology’s race problem does not begin or end with demographically adjusted norms	25
Origins and immunopathogenesis of autoimmune central nervous system disorders	25
Cognitive impairment and World Trade Centre-related exposures	24
Facing the urgency of therapies for progressive MS — a Progressive MS Alliance proposal	24
Gene therapy for primary mitochondrial diseases: experimental advances and clinical challenges	23
Neurodegenerative diseases associated with non-coding CGG tandem repeat expansions	23
Viral pathogens increase risk of neurodegenerative disease	23
A cultural approach to dementia — insights from US Latino and other minoritized groups	23
Headache in people with epilepsy	23
Pathogenic autoantibodies in multiple sclerosis — from a simple idea to a complex concept	22
The amyotrophic lateral sclerosis exposome: recent advances and future directions	22
Inequities in neurology amplified by the COVID-19 pandemic	22
Linking the cerebellum to Parkinson disease: an update	22
Genetic generalized epilepsies in adults — challenging assumptions and dogmas	22
Is Alzheimer disease a disease?	21
Facioscapulohumeral muscular dystrophy: the road to targeted therapies	21
Neurological telemedicine in the COVID-19 era	21
Pain-resolving immune mechanisms in neuropathic pain	21
Myasthenia gravis: the changing treatment landscape in the era of molecular therapies	19
Meningeal inflammation as a driver of cortical grey matter pathology and clinical progression in multiple sclerosis	18
Counting the neurological cost of COVID-19	18
Recessive cerebellar and afferent ataxias — clinical challenges and future directions	18
The childhood migraine syndrome	18
Addressing disparities in the global epidemiology of stroke	18
SARS-CoV-2 detected in olfactory neurons	17
Redefining cerebral palsies as a diverse group of neurodevelopmental disorders with genetic aetiology	17
Idiopathic intracranial hypertension: a step change in understanding the disease mechanisms	15
The challenges of anti-tau therapeutics in Alzheimer disease	15
Epilepsy and epileptiform activity in late-onset Alzheimer disease: clinical and pathophysiological advances, gaps and conundrums	15
Nutritional and metabolic factors in amyotrophic lateral sclerosis	15
Cell-based therapies for neurological disorders — the bioreactor hypothesis	14
Neuropsychological impairment in amyotrophic lateral sclerosis–frontotemporal spectrum disorder	13
Fundamental mechanistic insights from rare but paradigmatic neuroimmunological diseases	13
Isoform-dependent APOE secretion modulates neuroinflammation	13
Post-COVID dysautonomias: what we know and (mainly) what we don’t know	12
Mechanisms underlying HIV-associated cognitive impairment and emerging therapies for its management	12
Limbic-predominant age-related TDP43 encephalopathy (LATE) neuropathological change in neurodegenerative diseases	11
Multifaceted roles of APOE in Alzheimer disease	11
Inflammasomes in neurological disorders — mechanisms and therapeutic potential	11
Towards a global view of multiple sclerosis genetics	11
Cohort-guided insights into gene–environment interactions in autism spectrum disorders	10
Deciphering nociplastic pain: clinical features, risk factors and potential mechanisms	10
Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease	10
Getting specific: targeting Fc receptors in myasthenia gravis	10
Brain changes after COVID-19 — how concerned should we be?	10
Prospects for gene replacement therapies in amyotrophic lateral sclerosis	9
Psychiatric sequelae of traumatic brain injury — future directions in research	9
Neural cell state shifts and fate loss in ageing and age-related diseases	9

From precision diagnosis to precision treatment in epilepsy	9
Functional neurological disorder and placebo and nocebo effects: shared mechanisms	9
Genome-wide analysis furthers decoding of Alzheimer disease genetics	9
Defining traumatic encephalopathy syndrome — advances and challenges	9
The missing X factor in Alzheimer disease	9
Standardization and digitization of clinical data in multiple sclerosis	9
Mechanisms underlying phenotypic variation in neurogenetic disorders	8
Is it time for genetic modifiers to predict prognosis in Duchenne muscular dystrophy?	8
The translational potential of cholesterol-based therapies for neurological disease	8
T cells step up after SARS-CoV-2 vaccination with B cell depletion	8
Risk–benefit analysis of COVID-19 vaccines — a neurological perspective	8
Making headway — a role for CGRP in post-traumatic headache	7
Biomarkers in amyotrophic lateral sclerosis: current status and future prospects	7
Anti-inflammatory drugs could cause chronic pain	7
The African Stroke Organization — a new dawn for stroke in Africa	7
Artificial intelligence in epilepsy — applications and pathways to the clinic	7
Reactive astrocyte biomarkers mirror Alzheimer disease pathology	7
Potassium channel openers — novel triggers of aura and migraine	7
Changes in brain drainage systems are linked to Parkinson disease	7
Neurological manifestations of rhino-oculo-cerebral mucormycosis in the COVID-19 era	6
Does antiherpetic antiviral therapy reduce the risk of dementia?	6
Neuroinflammation, not amyloid-β deposition, associated with brain network dysfunction in AD	6
VEGFA mediates blood–brain barrier disruption in Parkinson disease	6
Ventricular enlargement caused by aducanumab	6
Digital assessment at home — mPower against Parkinson disease	6
Bidirectional brain–computer interface aids robotic arm control	6
Publisher Correction: Peripheral and central immune system crosstalk in Alzheimer disease — a research prospectus	6
Pathogenetic mechanisms and treatment targets in cerebral malaria	6
Barriers to implementation of evidence into clinical practice in low-resource settings	6
Development and implementation of new diagnostic technologies in neurology	5
Lessons from lockdown — behavioural interventions in migraine	5
The Parkinson disease connectome — insights from new imaging studies	5
Elevated risk of COVID-19 in people with dementia	5
Insights into epileptogenesis from post-traumatic epilepsy	5
Disease modification is not all — we need symptomatic therapies for Alzheimer disease	5
Cognitive criteria in HIV: greater consensus is needed	5
Extracellular protein homeostasis in neurodegenerative diseases	5
Endemic parkinsonism: clusters, biology and clinical features	5
Rare genetic brain disorders with overlapping neurological and psychiatric phenotypes	5
First trials test targeting of α-synuclein for Parkinson disease	5
Implications of research that excludes under-served populations	5
Aberrant protein networks in Alzheimer disease	5
Huntington disease-like 2: insight into neurodegeneration from an African disease	4
Approval of omaveloxolone for Friedreich ataxia	4
Astrocytic IL-3 could help microglia protect against Alzheimer disease	4
α-Synuclein-activated microglia are implicated in PD pathogenesis	4
Influence of amyloid-β on tau spread in Alzheimer disease explained	4
Neurostimulation for treatment of post-stroke impairments	4
Single-cell transcriptomics reveals neuroinflammation in severe COVID-19	4
Alzheimer disease blood biomarkers: considerations for population-level use	4
Brain organoids shed light on APOE genotype and Alzheimer disease pathology	4
Psychotic disorders as a framework for precision psychiatry	4
Transcriptomic mapping of the human cerebrovasculature	4
Exosomal microRNA is promising biomarker in PD	4
Advances in the therapeutic algorithm for myasthenia gravis	4
Targeting connexin hemichannels to treat temporal lobe epilepsy	3
Genome-wide association study identifies new risk loci for Alzheimer disease	3
Forensic neurology: a distinct subspecialty at the intersection of neurology, neuroscience and law	3
Rethink the classical view of cerebrospinal fluid production	3
The 5-HT1F receptor as the target of ditans in migraine — from bench to bedside	3
Ultrasound and antibodies — a potentially powerful combination for Alzheimer disease therapy	3
Neuroimmune interactions and COVID-19 in lung transplant recipients	3
Assessing prospective memory beyond experimental tasks	3
Neuropsychiatric symptoms in AD: the search for mechanisms	3
Impaired glymphatic drainage links amyloid and tau to cognitive dysfunction	3
Calcium dysregulation could underlie lysosomal impairment in AD	3
Parkinson disease psychosis: from phenomenology to neurobiological mechanisms	3
Treatments for AD: towards the right target at the right time	3
AI-based tools for the diagnosis and treatment of rare neurological disorders	3
New consensus guidelines on vaccination in multiple sclerosis	3
Treating epilepsy in forcibly displaced persons: timely, necessary, affordable	3
Pathway-based stratification of glioblastoma	3
Clinical outcomes evolve years after traumatic brain injury	3
A multiple hits hypothesis for memory dysfunction in Parkinson disease	3
Biomarker-based diagnosis of preclinical Alzheimer disease: time for the clinic?	3
Slowly expanding lesions are linked to multiple sclerosis progression	3
Neuroinflammation predicts cognitive decline in FTD	3
Dense-core plaques could be beneficial in AD	3
Looking for lights in the fog of long-term neurological COVID	2
Author Correction: The human connectome in Alzheimer disease — relationship to biomarkers and genetics	2
COVID-19 and the neurological disease therapeutic pipeline	2
APOE4 provokes tau aggregation via inhibition of noradrenaline transport	2
Parkinson disease and air pollution: does what we breathe matter?	2
Surprise neurovascular dysfunction in frontotemporal dementia	2
Early-onset dementia in autism spectrum disorder	2
Schizophrenia: genetic insights with clinical potential	2
Exosomal microRNAs may aid differential diagnosis of movement disorders	2
Restoring synapses in AD models	2
Microglia subset associated with high-grade glioma	2
FTD–ALS risk factors converge on the endolysosomal pathway	2
Microglial optogenetics triggers chronic pain in mice	2
Gaucher disease provides a unique window into Parkinson disease pathogenesis	2
Reply to ‘Cognitive criteria in HIV: greater consensus is needed’	2
Epstein–Barr virus and MS — a causal link	2
Assessing long-term effectiveness of MS treatment — a matter of debate	2